Tesamorelin
FDA-Approved GHRH Analogue for Visceral Fat
Tesamorelin is a synthetic analogue of GHRH approved by the FDA under the brand name Egrifta® for the reduction of excess visceral abdominal fat in HIV-infected adults with lipodys...
Formula
C221H366N72O67S
Molecular Weight
5135.9 g/mol
What is this compound?
Tesamorelin is a synthetic analogue of GHRH approved by the FDA under the brand name Egrifta® for the reduction of excess visceral abdominal fat in HIV-infected adults with lipodystrophy. It is one of the few peptides with an approved clinical indication, providing robust research foundation for its fat-targeting properties.
FDA-approved reduction of visceral abdominal fat
IGF-1 normalization in GH-deficient patients
Cardiovascular risk marker improvement
Improved body composition with minimal lean mass changes
Cognitive function research in MCI and Alzheimer's
Well-studied safety profile from clinical trials
How it works
Tesamorelin binds to GHRH receptors, stimulating pulsatile GH release which elevates IGF-1. The elevated GH/IGF-1 axis promotes lipolysis in visceral adipocytes. An added trans-3-hexenoic acid moiety stabilizes the molecule and extends its half-life compared to native GHRH....
Research imagery
Areas of investigation
Discovery to present
1970s
Discovery
Tesamorelin was first identified and characterized in research contexts.
2000s
Research
Preclinical studies expanded across multiple tissue types and disease models.
2010s
Clinical Progress
Phase III clinical trials demonstrated efficacy, leading to regulatory approval.
2024+
Current Interest
Active research continues with growing scientific interest and expanding publication volume.
Knowledge connections
Explore how Tesamorelin connects to mechanisms, research goals, related compounds, and scientific references.
Research calculations
Plan research protocols with precise reconstitution, dosing, and unit conversion tools.
Reconstitution Calculator
Bacteriostatic water ratios
Dose Calculator
Precise microgram dosing
Unit Converter
Syringe unit conversions
Compare with similar compounds
Frequently researched together
These compounds are commonly studied alongside Tesamorelin for complementary mechanism effects.
Loading...
Primary literature
Reference compilation in progress. See research highlights below.
Phase III trials show 15-18% reduction in visceral fat area over 26 weeks
Phase III trials show 15-18% reduction in visceral fat area over 26 weeks
Cognitive studies at Vanderbilt University show improvement in verbal memory and executive function
Cognitive studies at Vanderbilt University show improvement in verbal memory and executive function
Long-term safety data from HIV lipodystrophy cohorts establishes favorable tolerability
Long-term safety data from HIV lipodystrophy cohorts establishes favorable tolerability
Tesamorelin — Frequently asked
Tesamorelin is a synthetic analogue of GHRH approved by the FDA under the brand name Egrifta® for the reduction of excess visceral abdominal fat in HIV-infected adults with lipodystrophy. It is one of... Tesamorelin belongs to the Weight Loss research category and is studied for its fda-approved ghrh analogue for visceral fat.
Tesamorelin binds to GHRH receptors, stimulating pulsatile GH release which elevates IGF-1. The elevated GH/IGF-1 axis promotes lipolysis in visceral adipocytes. An added trans-3-hexenoic acid moiety stabilizes the molecule and extends its half-life compared to native GHRH.
FDA-approved reduction of visceral abdominal fat. IGF-1 normalization in GH-deficient patients. Cardiovascular risk marker improvement. Improved body composition with minimal lean mass changes. Cognitive function research in MCI and Alzheimer's. Well-studied safety profile from clinical trials.
Tesamorelin has the molecular formula C221H366N72O67S and a molecular weight of 5135.9 g/mol. This structural information is important for researchers studying receptor binding and pharmacokinetics.
Phase III trials show 15-18% reduction in visceral fat area over 26 weeks Cognitive studies at Vanderbilt University show improvement in verbal memory and executive function Long-term safety data from HIV lipodystrophy cohorts establishes favorable tolerability These findings are based on preclinical and clinical research. Tesamorelin is a research compound and these studies do not constitute medical advice.
Yes. Tesamorelin is FDA-approved under the brand name Egrifta® for the reduction of excess visceral abdominal fat in HIV-infected adults with lipodystrophy.
Tesamorelin belongs to the Weight Loss category, which focuses on compounds studied for their roles in metabolic regulation, growth hormone signaling, and targeted adipose tissue reduction. You can explore more compounds in this category on the Weight Loss pillar page.
Add to your cart
Select a variant to add Tesamorelin to your cart for comparison, protocol planning, and AI-assisted analysis.
Available Variants
Research Disclaimer
Tesamorelin is a research compound. All information is for educational and research purposes only. Not intended for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.